Biomarker hiring has become one of the highest-stakes technical searches at venture-backed biotech — a strong biomarker strategy defines patient selection, dose selection, and go/no-go readouts. Recruits Lab places biomarker scientists and leaders who bridge discovery, translational, and clinical implementation.
Biomarkers are the data that decide whether a clinical hypothesis holds. A weak biomarker hire shows up as undefined endpoints, missed PD signals, or a clinical trial that reads negative on the wrong measurement. The cost of getting biomarker hiring wrong is the trial that fails to learn anything actionable.
Recruits Lab places biomarker talent across biomarker discovery, biomarker assay development, translational biomarker strategy, and clinical biomarker leadership. Our practice spans Scientist through Director and VP levels for venture-backed biotech and specialty pharma.
Our recruiters understand the distinctions that matter — biomarker scientists with publication-quality discovery work versus those who have only run assays, biomarker strategists with real clinical implementation experience versus theoretical familiarity, and clinical biomarker leads with FDA biomarker qualification experience versus those without. We screen for true ownership.
Most biomarker searches at venture-backed companies struggle because the role sits between discovery, translational, clinical, and bioanalytical functions. The candidate has to bridge all four. We screen for that breadth.
Subscription pricing is what makes this work for the budgets venture-backed biomarker functions actually operate against.
Why this market is hard to recruit for. And how we solve each one.
Discovery biomarker work and clinical implementation are different skill sets. We map candidates to the right phase.
Genomic, proteomic, imaging, and functional biomarkers are distinct. We screen for the right specialty.
True CDx ownership is rare and valuable. We screen for direct experience.
Biomarker leads must talk credibly across discovery, clinical, and regulatory. We assess for it directly.
Senior biomarker talent is in chronic short supply. We manage offer and resign conversations.
Most biomarker work runs through CROs. We screen for the oversight skill set.
The repeatable system behind our 14-day average hire time.
We run a deep intake call with hiring managers and scientific leadership covering technical must-haves, dealbreakers, comp band, equity philosophy, and the cultural traits that predict success in your specific stage and program.
We build a fresh map of 80-150 qualified candidates from direct competitors, academic spinouts, CROs, and adjacent therapeutic areas. No database scraping — real research from a recruiter who understands the science.
Personalized outreach from a senior recruiter who can actually discuss your molecule, mechanism, or modality. Response rates run 3-5x higher than generalist agencies because the first message reads like it came from another scientist.
Five to eight vetted candidates with structured profile briefs covering technical fit, motivation, publication record where relevant, comp expectations, and risk factors. Not a resume dump — a decision document.
We manage offer construction, counter-offer scenarios, resign coaching, and start-date negotiation. Every placement carries a 90-day replacement guarantee at no additional fee.
Original observations from live searches in this specialty.
The biomarker scientist who discovered a signature in bulk-tissue RNA-seq is often not the person who will validate that signature for clinical use under CLIA. We split biomarker searches into 'discovery' and 'implementation' at intake and shortlist separately.
A Senior Director of Biomarker with IHC depth is not interchangeable with one with flow cytometry or ctDNA depth. Assay class-specific experience is more predictive of shortlist success than years or title. We calibrate to assay class in intake.
For programs approaching pivotal trial with a defined patient-selection biomarker, biomarker leaders with prior companion diagnostic (CDx) development experience are disproportionately valuable. The pool is small; we source against it directly.
2026 U.S. base salary ranges for biomarker roles at venture-backed and mid-cap life sciences companies. Excludes equity, bonus, and sign-on. Ranges reflect Series A through commercial-stage benchmarks.
| Role | Base Salary Range |
|---|---|
| Senior Scientist, Biomarker | $155K–$205K |
| Principal Scientist, Biomarker | $185K–$240K |
| Manager, Biomarker Strategy | $180K–$235K |
| Associate Director, Biomarker | $215K–$280K |
| Director, Biomarker Strategy | $245K–$315K |
| Senior Director, Biomarker | $290K–$370K |
| VP, Biomarker & Translational | $340K–$450K |
Source: Recruits Lab 2026 Life Sciences Compensation dataset.
Quick answers to the questions founders and hiring leaders ask most.
Biomarker recruiters source, screen, and qualify scientists and strategists across biomarker discovery, assay development, translational strategy, and clinical implementation. Recruits Lab specializes in biomarker and averages 14 days from kickoff to offer.
Industry average for director-level biomarker is 100 to 160 days. Recruits Lab averages 14 days.
Yes. CDx experience is a frequent search profile, particularly in oncology programs.
Subscription starts at $7,500 per month with unlimited active roles. Contingency is a flat 20 percent with a 90-day guarantee.
Yes. Imaging biomarker leads are part of the practice.
Director of Biomarker Strategy with IO CDx experience needed ahead of pivotal trial. Internal recruiting had filled none in five months.
Mapped 22 IO biomarker leaders nationally with CDx experience. Senior recruiter ran outbound, presented a four-person shortlist in 13 days.
Offer accepted in 20 days. CDx strategy was finalized ahead of pivotal trial start.
"Recruits Lab understood the science from day one. They sent four interview-ready candidates inside two weeks after our internal team had spent three months on the role."
"Their subscription model let us close three scientific hires in a single quarter for less than what a single retained search would have cost us."
Yes. Both are core biomarker practice areas.
Yes. Biomarker operations and vendor oversight are part of the practice.
Yes. Diagnostics companies hiring biomarker talent are part of the practice.
Yes. Imaging biomarker scientists and clinical imaging leads are routine searches.
Yes. Liquid biopsy and ctDNA biomarker scientists are a growing part of the practice.
Every placement carries a 90-day replacement guarantee. If a hire leaves or does not work out within the first 90 days, we run the search again at no additional fee.
Yes. We sign NDAs and routinely run confidential and stealth-mode searches for executive replacements, sensitive program leads, and pre-launch hires.
Book a free 30-minute hiring strategy review using the CTA on this page. We will scope the role, suggest a sourcing approach, and quote a subscription or contingency option that fits your stage.
Compensation data, hiring playbooks, case studies, and related recruiting specialties.
Four ways to engage. Pick whichever matches where you are.
30-minute strategy review with a senior recruiter. Free, no commitment.
Get startedTell us about the role. We respond with a calibration call within 24 hours.
Get startedSend a job description. We confirm fit and quote a subscription or contingency engagement.
Get startedSenior candidates: get represented to our active hiring pipeline.
Get startedRelated Resources
Hand-picked salary guides, market reports, and recruiter pages related to this topic. Authored by Darren Nelson and the Recruits Lab team.
Schedule a free 30-minute Hiring Strategy Review and walk away with a clear plan tailored to your roles.